Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 9/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.41 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.41 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.41 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.41 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.41 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169494 | 0.98 | SLC11A2 (0.54) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Bromide SCHEMBL4023680 | 0.81 | SLC11A2 (0.53) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Bromide SCHEMBL4167290 | 0.81 | SLC11A2 (0.53) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL4173293 | 0.79 | SLC11A2 (0.54) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL4170444 | 0.79 | SLC11A2 (0.54) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL13908675 | 0.79 | SLC11A2 (0.54) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Bromide SCHEMBL4161416 | 0.71 | SLC11A2 (0.97) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Bromide SCHEMBL2810291 | 0.69 | SLC11A2 (0.70) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL4155854 | 0.69 | SLC11A2 (1.00) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 | |
| Bromide SCHEMBL4008068 | 0.68 | SLC11A2 (0.62) | SLC11A2TP53CYP3A4SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | SLC11A2 77/4885TP53 2828/4885CYP3A4 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.